AstraZeneca is to invest £120m in a new facility at its manufacturing site in Macclesfield, Cheshire, to continue production of Zoladex, an injectable treatment for patients with prostate cancer.
The investment is said to secure 300 existing Zoladex jobs at the site and will create over 200 temporary jobs during the construction and commissioning phase between now and early 2017.
Zoladex is currently the company’s fifth largest selling brand with annual global sales in the region of $1bn.
The continued global demand for Zoladex, particularly in Japan and emerging markets including China and Russia, has resulted in the decision to invest in replacing some of the existing facilities where the medicine is currently produced at the Macclesfield site.
The building of the new facility will begin in 2013 and is due to be completed by 2016. Products manufactured in the new facility will begin to be supplied to markets in 2017.